Logo image of ENVB

ENVERIC BIOSCIENCES INC (ENVB) Stock Fundamental Analysis

NASDAQ:ENVB - Nasdaq - US29405E4061 - Common Stock - Currency: USD

1.23  -0.03 (-2.38%)

Fundamental Rating

2

Taking everything into account, ENVB scores 2 out of 10 in our fundamental rating. ENVB was compared to 198 industry peers in the Pharmaceuticals industry. While ENVB seems to be doing ok healthwise, there are quite some concerns on its profitability. ENVB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ENVB had negative earnings in the past year.
ENVB had a negative operating cash flow in the past year.
In the past 5 years ENVB always reported negative net income.
In the past 5 years ENVB always reported negative operating cash flow.
ENVB Yearly Net Income VS EBIT VS OCF VS FCFENVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -310.62%, ENVB is doing worse than 92.42% of the companies in the same industry.
ENVB has a Return On Equity of -601.14%. This is in the lower half of the industry: ENVB underperforms 79.29% of its industry peers.
Industry RankSector Rank
ROA -310.62%
ROE -601.14%
ROIC N/A
ROA(3y)-228.5%
ROA(5y)-175.33%
ROE(3y)-413.38%
ROE(5y)-299.5%
ROIC(3y)N/A
ROIC(5y)N/A
ENVB Yearly ROA, ROE, ROICENVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

ENVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENVB Yearly Profit, Operating, Gross MarginsENVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

More info and screens

5

2. Health

2.1 Basic Checks

ENVB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ENVB has been increased compared to 5 years ago.
There is no outstanding debt for ENVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENVB Yearly Shares OutstandingENVB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
ENVB Yearly Total Debt VS Total AssetsENVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

ENVB has an Altman-Z score of -56.75. This is a bad value and indicates that ENVB is not financially healthy and even has some risk of bankruptcy.
ENVB has a worse Altman-Z score (-56.75) than 91.92% of its industry peers.
ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -56.75
ROIC/WACCN/A
WACCN/A
ENVB Yearly LT Debt VS Equity VS FCFENVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ENVB has a Current Ratio of 1.84. This is a normal value and indicates that ENVB is financially healthy and should not expect problems in meeting its short term obligations.
ENVB has a Current ratio of 1.84. This is in the lower half of the industry: ENVB underperforms 62.12% of its industry peers.
ENVB has a Quick Ratio of 1.84. This is a normal value and indicates that ENVB is financially healthy and should not expect problems in meeting its short term obligations.
ENVB's Quick ratio of 1.84 is in line compared to the rest of the industry. ENVB outperforms 41.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
ENVB Yearly Current Assets VS Current LiabilitesENVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.57% over the past year.
EPS 1Y (TTM)82.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ENVB will show a very strong growth in Earnings Per Share. The EPS will grow by 38.43% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.88%
EPS Next 2Y38.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENVB Yearly Revenue VS EstimatesENVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2027 2028 2029 2030 2031 50M 100M
ENVB Yearly EPS VS EstimatesENVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ENVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENVB Price Earnings VS Forward Price EarningsENVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENVB Per share dataENVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as ENVB's earnings are expected to grow with 38.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (5/16/2025, 10:46:32 AM)

1.23

-0.03 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners7.16%
Inst Owner Change-4.43%
Ins Owners0.07%
Ins Owner Change0%
Market Cap3.04M
Analysts82.86
Price Target55.9 (4444.72%)
Short Float %7.02%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-945.64%
Min EPS beat(2)-1946.04%
Max EPS beat(2)54.75%
EPS beat(4)3
Avg EPS beat(4)-453.25%
Min EPS beat(4)-1946.04%
Max EPS beat(4)55.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)558.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)44.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.91
P/tB 1.96
EV/EBITDA N/A
EPS(TTM)-21.3
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-5.71
FCFYN/A
OCF(TTM)-5.71
OCFYN/A
SpS0
BVpS0.64
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -310.62%
ROE -601.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-228.5%
ROA(5y)-175.33%
ROE(3y)-413.38%
ROE(5y)-299.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -56.75
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.23%
EPS Next Y95.88%
EPS Next 2Y38.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.01%
EBIT Next 3YN/A
EBIT Next 5Y14.36%
FCF growth 1Y20.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.82%
OCF growth 3YN/A
OCF growth 5YN/A